Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer

Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69

Published:2018-02-14 Issue: Volume: Page:
ISSN:
Container-title:General Session Abstracts
language:
Short-container-title:

Author:

Schneeweiss A,Jackisch C,Schmatloch S,Aktas B,Denkert C,Schem C,Wiebringhaus H,Kümmel S,Rhiem K,Warm M,Fasching PA,Just M,Hanusch C,Hackmann J,Blohmer JU,Gerber B,Furlanetto J,von Minckwitz G,Nekljudova V,Loibl S,Untch M

Publisher

American Association for Cancer Research

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary/Neoadjuvant Treatments;Breast Cancer Essentials;2021

2. Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer;Geburtshilfe und Frauenheilkunde;2019-10

3. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study;Annals of Oncology;2019-08

4. Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers;The Lancet Oncology;2019-07

5. Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer;Geburtshilfe und Frauenheilkunde;2019-03